MRI Safe Neurostimulation Systems Market Size, Share and Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2025 – 2034

MRI Safe Neurostimulation Systems Market Size

The global MRI safe neurostimulation systems market generated notable revenues in 2024 and is expected to see a decent CAGR during 2025-2034 driven by the increasing preference towards subsequently non-invasive treatment approaches for chronic neurological disease diagnostic methods, like Parkinson’s disease, epilepsy, and chronic pain increasing prevalence of chronic neurological disorders is significantly contributing to the market. As per Parkinson’s Organization, approximately 1.1 million people in the United States are currently living with Parkinson’s disease (PD), and this figure is projected to increase to 1.2 million by 2030.  
 

Neurostimulation systems have shown to be useful in modulating nerve activity, and improved patient quality of life. Traditionally, the system loud many patients detecting a compatibility, with MRI, to access needed imaging tests. MRI safe neurostimulation systems have provided patients with the initial ability to obtain safe imaging without removing or disabling the implant, which is a godsend for many patients to receive proper care in the care setting. The increase in global neurological disorders, higher older population, and technological advances are largely attributed to stimulating the adoption of MRI safe neurostimulation devices.
 

Patient safety with newer systems becomes so exciting by allowing for imaging flexibility, which further encourages our patients to rethink their devices in our collective progress forward. Furthermore, health systems in higher resource systems in developed markets are investing in new more advanced neurostimulator technologies, while emerging markets are seeing increased demand for access to these systems based on new spendable wealth, and better healthcare infrastructure with more opportunity in health markets. Historical barriers to the market for expensive class III devices, and questionable reimbursement in some regions, are chances for missing out on much bigger rewards.
 

MRI Safe Neurostimulation Systems Market Trends

The market is experiencing significant trends. One trend is the increased movement to personalized and closed-loop neurostimulation systems, allowing them to monitor the patient and provide adaptive stimulation according to patient feedback in real-time maneuvers. This technology facilitates the treatment, improves outcomes, and limits the patient’s exposure to side effects. Another trend is the greater use of rechargeable, miniaturized devices that are convenient for patients because they lessen complications with unnecessary surgical replacements and improve the overall quality of life for the patient.
 

The movement toward supporting the concomitancy of these devices with digital health tools, including mobile applications and wearable interfaces empowers patients to manage their condition and share relevant real-time data with healthcare providers. There is also an expanded use of MRI safe neurostimulation systems, which previously were only used for chronic pain and Parkinson's Disease, currently include depression, Alzheimer's disease, stroke rehabilitation, and urinary incontinence.
 

The market is also expanding geographically into Asia-Pacific and Latin America, fueled by increased healthcare investment and public-private partnerships. Lastly, we are starting to see regulatory convergence in many countries with the introduction of accelerated approval pathways shortening the time to market products and support further innovation.
 

MRI Safe Neurostimulation Systems Market Analysis

The deep brain stimulation (DBS) segment in the market held a notable share in 2024. DBS is indicated for a variety of neurological conditions, including Parkinson's disease, essential tremor, dystonia, and epilepsy, among other indications where long-term pharmacological intervention is ineffective or creates undesirable side effects. The growth of this segment is driven by higher international incidence of Parkinson’s and epilepsy especially in older age populations which have a higher prevalence of these diseases.
 

Clearly, patients and neurosurgeons alike prefer MRI-safe DBS systems because they confer advanced imaging compatibility while having no impact on stimulation effectiveness. This allows patients to have necessary and routine diagnostic MRI scans without any consequences to the DBS therapy. The advancement of the electrode form factor, battery life, and?closed-loop feedback further supports improved treatment outcomes and patient satisfaction.
 

Furthermore, the segment is seeing a movement towards rechargeable systems with smaller profiles and more precise targeting of the DBS to optimize clinical benefits while minimizing side effects. With regulatory bodies continuing to approve more MRI-compatible systems and better, less invasive neuro-surgical techniques, the market for DBS continues to grow. The other leading market players are also making substantial investments in DBS.
 

The implantable segment in the MRI safe neurostimulation systems market will grow at a robust rate during 2025-2034. Implantable neurostimulators are a mainstay in the management of chronic pain, depression, bladder dysfunction, and other refractory neurological diseases. When activated, implantable neurostimulators generate electrical impulses to specific nerves, either modulating pain signals or generating a therapeutic response. Limited MRI compatibility has historically restricted imaging options available to patients with implantable neurostimulators.
 

These limitations were dramatically resolved with the introduction of MRI safe technologies. These technologies now enable full diagnosis and treatment. In the implantable aspect, advancement is due to multiple reasons with technological advancements being a key reason, such as miniaturization, wireless capability, and providing a unique programmable, customizable therapy to sell to the patient based on their specific therapeutic needs. Several major manufacturers are also working to develop implantable neurostimulators with longer battery life and MRI conditional labeling for 1.5T and 3T MRI scanners.
 

North America MRI safe neurostimulation systems market held the largest share in 2024 and is estimated to grow at a notable CAGR during 2025-2034 due to a supportive healthcare infrastructure, an acceptance of innovative medical technology, and a rise in instances of neuromodulation compatible conditions. The aggressive effort to treat chronic responses by the market saw invention with the support of major players like Medtronic and Abbott, Boston Scientific who are providing more medical imaging-compatible devices to promote and enhance compliance.
 

The payouts from insurers help to ensure the marketing and production of MRI-compatible devices is investment worthy. The favorable reimbursements from insurers, and favorable regulations are also aiding in heavy product penetration in the healthcare space. Also, to highly antiquated merge of physicians and patients to understand the significance of purchasing MRI facilitation, particularly their avoidance of long-term complications to make diagnostics, redesigns, or removal, led to the region's anticipatory energy.
 

The amplifying of trial processes and new hospitals focusing on particularly or especially innovative canters medical research, and medical imaging facility associations and cooperatives is heavily influencing the market. There have been significant technological leaps in medical imaging in this country, including medicines to bring method and effort.
 

MRI Safe Neurostimulation Systems Market Share

Major companies operating in the MRI safe neurostimulation systems industry include:

• Nevro Corp.
• Biotronik
• Medtronic
• Sorin
• Neuronetics
• Cyberonics
• AADCO Medical
• St. Jude Medical
• Codman & Shurtleff’s
• Boston Scientific
   

Top players in the market are implementing a variety of approaches to bolster their position in the market. The most common strategies include large investments in R&D, which drive product innovation. These efforts have led to the development of miniaturized, rechargeable, and closed-loop systems. Companies are also collaborating with research institutions and technology firms to accelerate R&D cycles and clinical validation.
 

Expansion into emerging markets is another key strategy. These regions often face a growing burden of neurological diseases and have improving healthcare infrastructures. Businesses are also engaging with regulators to streamline the approval process. This helps fast-track product and labeling approvals, particularly for MRI-conditional systems. Educational initiatives for physicians are being implemented to promote the use of MRI-safe products. At the same time, companies are investing in direct-to-patient marketing campaigns to increase awareness. These efforts help strengthen brand visibility and encourage adoption. Overall, such strategies enhance brand presence and competitiveness in a rapidly evolving market focused on innovation.
 

MRI Safe Neurostimulation Systems Industry News

• In January 2025, The U.S. Food and Drug Administration (FDA) granted an expanded label approval for whole-body MRI-conditional use of neurostimulation system, based on its earlier clearance for peripheral nerve stimulation (PNS) therapy.